Altimmune Announces CEO Transition and Succession Plan
Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong...
Clinical Trial
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet...
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac...
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a...
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),...
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK)...
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...
GENFIT Announces Appointment of new Chief Medical Officer
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to...
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as...
Thanksgiving Wishes to the DEA’s Anti Cannabis Holdouts – And Gently Suggests They Spend a Moment Thinking About Patients Waiting for Legal Medicine
MMJ Wishes DEA Officials a Happy Thanksgiving - While Reminding Them That Huntington's Chorea Doesn't Take Holidays. WASHINGTON, D.C. /...
In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations
AUSTIN, Texas and TOKYO, Nov. 27, 2025 /PRNewswire/ -- According to DataM Intelligence, the In-Silico Clinical Trials Market Size was...
Beyond Air® Announces Transition of Chief Financial Officer
Launched search for permanent successorGARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air”...
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”),...
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real...
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce...
Mural Health Expands Offering to Include Meal Delivery Services for Clinical Trial Participants
BERWYN, Pa., Nov. 26, 2025 /PRNewswire/ -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, today announced the expansion...